Collegium Pharmaceutical, Inc. (COLL) Return on equity 2016–2025
Collegium Pharmaceutical, Inc. (COLL) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
20.8%FY2025 · since FY2016: -69.8% → 20.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 20.8% | -9.4 pp |
| FY2024 | 30.2% | +5.6 pp |
| FY2023 | 24.6% | +37.5 pp |
| FY2022 | -12.8% | -48.1 pp |
| FY2021 | 35.2% | +20.9 pp |
| FY2020 | 14.4% | +40.4 pp |
| FY2019 | -26.0% | +16.7 pp |
| FY2018 | -42.7% | +29.2 pp |
| FY2017 | -71.9% | -2.1 pp |
| FY2016 | -69.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More COLL financial trends
COLL RevenueCOLL Net incomeCOLL Net marginCOLL Gross profitCOLL Gross marginCOLL Operating incomeCOLL Operating marginCOLL Operating cash flowCOLL Free cash flowCOLL Capital expendituresCOLL Stock buybacksCOLL Dividends paidCOLL Total assetsCOLL Total liabilitiesCOLL Shareholders’ equityCOLL overview →